BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11747721)

  • 1. Rapid identification of Bordetella pertussis pertactin gene variants using LightCycler real-time polymerase chain reaction combined with melting curve analysis and gel electrophoresis.
    Mäkinen J; Viljanen MK; Mertsola J; Arvilommi H; He Q
    Emerg Infect Dis; 2001; 7(6):952-8. PubMed ID: 11747721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan.
    Kodama A; Kamachi K; Horiuchi Y; Konda T; Arakawa Y
    J Clin Microbiol; 2004 Dec; 42(12):5453-7. PubMed ID: 15583264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple Algorithm for Identification of Bordetella pertussis Pertactin Gene Variants.
    Muyldermans G; Piérard D; Hoebrekx N; Advani R; Van Amersfoorth S; De Schutter I; Soetens O; Eeckhout L; Malfroot A; Lauwers S
    J Clin Microbiol; 2004 Apr; 42(4):1614-9. PubMed ID: 15071014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland.
    Mooi FR; He Q; van Oirschot H; Mertsola J
    Infect Immun; 1999 Jun; 67(6):3133-4. PubMed ID: 10338531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis.
    Mäkinen J; Mertsola J; Viljanen MK; Arvilommi H; He Q
    J Clin Microbiol; 2002 Jun; 40(6):2213-6. PubMed ID: 12037089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.
    Martin SW; Pawloski L; Williams M; Weening K; DeBolt C; Qin X; Reynolds L; Kenyon C; Giambrone G; Kudish K; Miller L; Selvage D; Lee A; Skoff TH; Kamiya H; Cassiday PK; Tondella ML; Clark TA
    Clin Infect Dis; 2015 Jan; 60(2):223-7. PubMed ID: 25301209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003.
    Byrne S; Slack AT
    BMC Infect Dis; 2006 Mar; 6():53. PubMed ID: 16542440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.
    Pawloski LC; Queenan AM; Cassiday PK; Lynch AS; Harrison MJ; Shang W; Williams MM; Bowden KE; Burgos-Rivera B; Qin X; Messonnier N; Tondella ML
    Clin Vaccine Immunol; 2014 Feb; 21(2):119-25. PubMed ID: 24256623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children.
    Mastrantonio P; Spigaglia P; Oirschot HV; van der Heide HGJ; Heuvelman K; Stefanelli P; Mooi FR
    Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():2069-2075. PubMed ID: 10463173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Manifestations and Molecular Characterization of Pertactin-Deficient and Pertactin-Producing Bordetella pertussis in Children, Philadelphia 2007-2014.
    Vodzak J; Queenan AM; Souder E; Evangelista AT; Long SS
    Clin Infect Dis; 2017 Jan; 64(1):60-66. PubMed ID: 27624959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
    Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D
    Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.
    Zeddeman A; van Gent M; Heuvelman CJ; van der Heide HG; Bart MJ; Advani A; Hallander HO; Wirsing von Konig CH; Riffelman M; Storsaeter J; Vestrheim DF; Dalby T; Krogfelt KA; Fry NK; Barkoff AM; Mertsola J; He Q; Mooi F
    Euro Surveill; 2014 Aug; 19(33):. PubMed ID: 25166348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genetic variability of Bordetella pertussis strains. Part I. Current knowledge].
    Gzyl A; Augustynowicz E; Gniadek G; Slusarczyk J
    Przegl Epidemiol; 2003; 57(1):181-92. PubMed ID: 12926327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years.
    Weber C; Boursaux-Eude C; Coralie G; Caro V; Guiso N
    J Clin Microbiol; 2001 Dec; 39(12):4396-403. PubMed ID: 11724851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor.
    Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E
    Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years.
    Tsang RS; Shuel M; Jamieson FB; Drews S; Hoang L; Horsman G; Lefebvre B; Desai S; St-Laurent M
    Int J Infect Dis; 2014 Nov; 28():65-9. PubMed ID: 25244999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines.
    Zomer A; Otsuka N; Hiramatsu Y; Kamachi K; Nishimura N; Ozaki T; Poolman J; Geurtsen J
    Microb Genom; 2018 May; 4(5):. PubMed ID: 29771235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999.
    Cassiday P; Sanden G; Heuvelman K; Mooi F; Bisgard KM; Popovic T
    J Infect Dis; 2000 Nov; 182(5):1402-8. PubMed ID: 11023463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli.
    Hijnen M; van Gageldonk PG; Berbers GA; van Woerkom T; Mooi FR
    Protein Expr Purif; 2005 May; 41(1):106-12. PubMed ID: 15802227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan.
    Otsuka N; Han HJ; Toyoizumi-Ajisaka H; Nakamura Y; Arakawa Y; Shibayama K; Kamachi K
    PLoS One; 2012; 7(2):e31985. PubMed ID: 22348138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.